Belzutifan metabolism and transport are influenced by specific genes such as UGT2B17, CYP2C19, and CYP3A4, where genetic variations in CYP2C19 significantly affect the drug's pharmacokinetics, altering plasma levels and impacting efficacy and safety. Additionally, transporter genes like ABCB1, SLCO1B1, SLCO1B3, and SLC47A2 play roles in the drug's absorption and elimination, affecting its bioavailability and clearance, which are crucial for personalized dosing strategies.